Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 400-830-7 | CAS number: 104810-48-2 EVERSORB 80; TINUVIN 1130; TINUVIN 213
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study, GLP compliance
Data source
Reference
- Reference Type:
- other: Body responsible for the test
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: 87/302/EEC p.8 (See comments)
- GLP compliance:
- yes
Test material
- Reference substance name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- EC Number:
- 400-830-7
- EC Name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- Cas Number:
- 104810-48-2
- Molecular formula:
- (C2H4O)nC38H40N6O5
- IUPAC Name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene); α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- Reference substance name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene) α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
- IUPAC Name:
- A mixture of: α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-hydroxypoly(oxyethylene) α-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyl-ω-3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionyloxypoly(oxyethylene)
Constituent 1
Constituent 2
Test animals
- Species:
- rat
Administration / exposure
- Route of administration:
- oral: unspecified
- Details on oral exposure:
- Method of administration:
Gavage - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Test duration: 90 days
- No. of animals per sex per dose:
- Male: 16 animals at 0 mg/kg bw/day
Male: 10 animals at 2 mg/kg bw/day
Male: 10 animals at 5 mg/kg bw/day
Male: 10 animals at 50 mg/kg bw/day
Male: 20 animals at 10 mg/kg bw/day
Female: 16 animals at 0 mg/kg bw/day
Female: 10 animals at 2 mg/kg bw/day
Female: 10 animals at 5 mg/kg bw/day
Female: 10 animals at 50 mg/kg bw/day
Female: 20 animals at 10 mg/kg bw/day
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no specific treatment-related clinical signs.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- There were no specific treatment-related clinical signs.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Bodyweight gain was reduced by 8% in top dose males only /statistically significant, P<0.01) and was considered treatment-related. (Non-significant effects on bodyweight gain were also seen in other groups).
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Food consumption was unaddected.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no opthalmologic effects.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- platelet counts were increased (statistically significant) in all male groups. The increases were dose-related and resolved during the recovery period. There were no other treatment-related haematological effects.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Details on results:
- Clinical observations:
SIGNS OF TOXICITY:
Deaths: 4/16 males, 1/16 females (0 mg/kg/day); 1/10 females (2 mg/kg/day); 1/10 males (5 mg/kg/day). No deaths were considered treatment-related: two were due to gavage errors. No cause was established for the others.
There were no specific treatment-related clinical signs.
Bodyweight gain was reduced by 8% in top dose males only /statistically significant, P<0.01) and was considered treatment-related. (Non-significant effects on bodyweight gain were also seen in other groups). Food consumption was unaddected.
There were no opthalmologic effects.
Haematology: platelet counts were increased (statistically significant) in all male groups. The increases were dose-related and resolved during the recovery period. There were no other treatment-related haematological effects.
Clinical chemistry: Alkaline phosphatase activity was increased (statistically significant) in males in the 10 (1.5 times) and 50 mg/kg/day (2.9 times) goups and in females in the group (1.4 times). It was normal in both sexes in the recovery groups. Albumin concentrations were increased in males and females from the 10 and 50 mg/kg/day groups and globulins were decreased in these groups. All plasma protein concentrations were normal in recovery group animals except beta-globulin which was still decreased. Plasma glucose was increased in top dose group males. Aminotransferases were reduced in activity in all test groups but activity was generally within the rang of that of that of the control animals, and was the same as control levels in the recovery groups.
Effects in organs:
Fross adrenal weights were decreased and relative kidney and testes weights increased in males of the top dose group. Liver weights (gross) were increased in all rats in the 5, 10 and 50 mg/kg/day groups /by 85% in males, 46% in femals in the top dose group) and relative liver weights were also increased in males in the 2 mg/kg/day group. The livers of many male rats were visibly enlarged. There were no significant differences in organ weights in the recovery group animals. The only microscopic changes seen which could be related to treatment were minimal to slight hepatic cell hypertrophy in 3/10 top dose group male animals. Chronic necrosis was seen in the liver of 1/10 of the same group.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.